RT Journal Article
SR Electronic
T1 CMV seropositivity in older adults changes T cell functionality, but does not prevent antibody or cellular SARS-CoV-2 vaccine responses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.27.22275673
DO 10.1101/2022.05.27.22275673
A1 Jessica A. Breznik
A1 Angela Huynh
A1 Ali Zhang
A1 Lucas Bilaver
A1 Hina Bhakta
A1 Hannah D. Stacey
A1 Jann C. Ang
A1 Jonathan L. Bramson
A1 Ishac Nazy
A1 Matthew S. Miller
A1 Judah Denburg
A1 Andrew P. Costa
A1 Dawn M. E. Bowdish
A1 other members of the COVID-in-LTC Investigator Group
YR 2022
UL http://medrxiv.org/content/early/2022/05/28/2022.05.27.22275673.abstract
AB It has been previously reported that chronic infection with human cytomegalovirus (CMV) may contribute to poor vaccine responses against de novo antigens in older adults. We assessed effects of CMV serostatus on antibody quantity and quality, as well as cellular memory responses, after 2 and 3 SARS-CoV-2 mRNA vaccine doses, in older adults in congregate living facilities. CMV serostatus did not affect anti-Spike and anti-RBD IgG antibody levels, nor neutralization capacity against wildtype or beta variants of SARS-CoV-2. CMV seropositivity altered T cell expression of senescence-associated markers and increased TEMRA cell numbers, as has been previously reported; however, this did not impact the Spike-specific CD4+ T cell memory responses. CMV seropositive individuals did not have a higher incidence of COVID-19, though prior infection influenced humoral immunity. Therefore, CMV seropositivity may alter T cell composition but does not impede humoral or cellular memory responses after SARS-CoV-2 mRNA vaccination in older adults.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the COVID-19 Immunity Task Force of the Public Health Agency of Canada.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Hamilton Integrated Research Ethics Board of McMaster University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not available without prior approval from the Hamilton Integrated Research Ethics Board (HiREB).